Credit facility option · Biotech
Delix Therapeutics secures $10 million credit-facility option with Comerica Bank
The facility option was announced alongside a separate convertible-note financing in January 2022.
Delix Therapeutics announced a $10 million strategic credit-facility option with Comerica Bank on January 10, 2022. The partnership involved the bank’s Technology and Life Sciences practice.
The option gave the neuroplastogen developer access to additional financing alongside its convertible notes. The announcement did not state that the full facility had been drawn.
Use of funds
Advance neuroplastogen development and expand pipeline
Funding history
Credit facility option · This round≤$10M
Series A$70M